FDA Adds Advisers as Review Finds Pharma Ties

The FDA is adding new voices to its advisory committees as an external analysis documents how often patient and consumer representatives have undisclosed ties to drug industry-funded groups. STAT reported on Oct. 13 that a Health Affairs Scholar analysis of FDA advisory meetings over two decades found nearly 40 percent involved a patient or consumer representative with an active connection to an advocacy group funded by pharmaceutical companies. According to the report, more than one in ten meetings involved a representative whose organization had received money from the drugmaker whose medicine was under review, and most of those ties were not disclosed.

The agency also named four voting members to the Tobacco Products Scientific Advisory Committee, according to an Oct. 15 report in Vaping Post. The public representative, Kim Murray, described herself as a tobacco harm reduction advocate and has been listed as a research fellow for the Consumer Center of the Taxpayers Protection Alliance, which does not disclose funding and has staff links to organizations that received tobacco industry money, according to the University of Bath's Tobacco Tactics project cited in the report. The new appointments fill four seats that had been empty since Jan. 31, 2026, and the FDA is still seeking nominations for two voting vacancies, with first consideration for submissions received by Dec. 14, 2026. The FDA asks nominees to list their financial holdings, employment, grants and contracts so reviewers can check for possible conflicts; nearly all non-federal members serve as special government employees.

How the current dispute began

In July the Pharmacy Compounding Advisory Committee considered seven unapproved peptides for the 503A bulk drug substances list, which compounding pharmacies use under Section 503A of the Food, Drug, and Cosmetic Act. On July 23 and 24, the committee recommended adding six of the seven: epitalon, semax, BPC-157, KPV, TB-500 and MOTS-C, and voted against emideltide. The votes were recommendations, not final agency action; the FDA would still decide whether to proceed through formal rulemaking. FDA scientists had recommended against all seven, citing limited clinical data and poor characterization of the substances.

The panel drew attention after the FDA added eight temporary voting members ahead of the meeting, and after reports noted possible conflicts involving members connected to clinics and businesses that supply peptides. A Mintz analysis explained that an advisory recommendation has no immediate legal effect and that adding a substance to the 503A list is not an FDA approval; state pharmacy boards, not FDA, primarily oversee 503A compounders. The analysis also said any future FDA move could face an Administrative Procedure Act challenge because existing rules list specific evaluation criteria and market demand is not among them.

A lawsuit filed on Aug. 19 by the Physicians Committee for Responsible Medicine against HHS and USDA in the U.S. District Court for the District of Columbia alleged that eight of nine researchers selected for a scientific review behind the updated dietary guidelines had financial relationships with food-sector groups such as the National Cattlemen's Beef Association and the National Dairy Council. The complaint also said the researchers were not screened for conflicts through a recusal review or given the ethics training the Federal Advisory Committee Act requires. The lawsuit asks the court to withdraw the guidelines and block their use in future policy decisions.

A commentary in The Commonwealth Times alleged that several peptide panelists were appointed immediately before the meeting and had ties to businesses that stood to gain money from the recommendation. The commentary argued that the committee vote did not require FDA to approve the peptides but could help HHS Secretary Robert F. Kennedy Jr. loosen regulations in the future.

Where the new appointments fit

The Health Affairs Scholar analysis noted that FDA has detailed conflict rules for scientific advisory members, but the rules for patient and consumer representatives are not as well developed, especially for industry money flowing to advocacy groups whose members sit on committees.